MIRA vs. BMY
MIRA (MIRA Pharmaceuticals Inc. Common Stock) and BMY (Bristol-Myers Squibb Company) are both stocks. Both operate in the Drug Manufacturers - General industry within the Healthcare sector. Over the past year, MIRA returned -18.11% vs 24.26% for BMY. At a 0.09 correlation, their price movements are largely independent.
Performance
MIRA vs. BMY - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, MIRA achieves a -36.82% return, which is significantly lower than BMY's 5.24% return.
MIRA
- 1D
- 0.26%
- 1M
- -3.83%
- YTD
- -36.82%
- 6M
- -40.00%
- 1Y
- -18.11%
- 3Y*
- —
- 5Y*
- —
- 10Y*
- —
BMY
- 1D
- 1.52%
- 1M
- -6.61%
- YTD
- 5.24%
- 6M
- 4.58%
- 1Y
- 24.26%
- 3Y*
- -0.64%
- 5Y*
- 0.61%
- 10Y*
- 1.07%
MIRA vs. BMY - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | |
|---|---|---|---|---|
MIRA MIRA Pharmaceuticals Inc. Common Stock | -36.82% | 32.46% | 8.57% | -85.00% |
BMY Bristol-Myers Squibb Company | 5.24% | 0.11% | 15.81% | -16.06% |
Correlation
The correlation between MIRA and BMY is 0.12, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.12 |
Correlation (All Time) Calculated using the full available price history since Aug 3, 2023 | 0.09 |
Fundamentals
MIRA:
-$1.57
BMY:
$3.57
MIRA:
$0.00
BMY:
$48.48B
MIRA:
$0.00
BMY:
$33.33B
MIRA:
-$6.93M
BMY:
$13.34B
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
MIRA vs. BMY — Risk / Return Rank
MIRA
BMY
MIRA vs. BMY - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for MIRA Pharmaceuticals Inc. Common Stock (MIRA) and Bristol-Myers Squibb Company (BMY). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| MIRA | BMY | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -1.13 | ||
| Sortino ratioReturn per unit of downside risk | -1.27 | ||
| Omega ratioGain probability vs. loss probability | 1.02 | 1.17 | -0.15 |
| Calmar ratioReturn relative to maximum drawdown | -0.33 | 1.95 | -2.28 |
| Martin ratioReturn relative to average drawdown | -0.51 | 4.41 | -4.92 |
Loading charts...
Drawdowns
MIRA vs. BMY - Drawdown Comparison
The maximum MIRA drawdown since its inception was -92.69%, which is greater than BMY's maximum drawdown of -72.03%. Use the drawdown chart below to compare losses from any high point for MIRA and BMY.
Loading charts...
Drawdown Indicators
| MIRA | BMY | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -92.69% | -72.03% | -20.66% |
Max Drawdown (1Y)Largest decline over 1 year | -54.46% | -12.53% | -41.93% |
Max Drawdown (3Y)Largest decline over 3 years | — | -36.02% | — |
Max Drawdown (5Y)Largest decline over 5 years | — | -47.67% | — |
Max Drawdown (10Y)Largest decline over 10 years | — | -47.67% | — |
Current DrawdownCurrent decline from peak | -87.14% | -20.09% | -67.05% |
Average DrawdownAverage peak-to-trough decline | -78.42% | -22.38% | -56.04% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 35.84% | 5.51% | +30.33% |
Volatility
MIRA vs. BMY - Volatility Comparison
MIRA Pharmaceuticals Inc. Common Stock (MIRA) has a higher volatility of 21.60% compared to Bristol-Myers Squibb Company (BMY) at 8.49%. This indicates that MIRA's price experiences larger fluctuations and is considered to be riskier than BMY based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| MIRA | BMY | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 21.60% | 8.49% | +13.11% |
Volatility (6M)Calculated over the trailing 6-month period | 45.80% | 18.04% | +27.76% |
Volatility (1Y)Calculated over the trailing 1-year period | 79.19% | 26.96% | +52.23% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 392.15% | 24.08% | +368.07% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 392.15% | 25.30% | +366.85% |
Dividends
MIRA vs. BMY - Dividend Comparison
MIRA has not paid dividends to shareholders, while BMY's dividend yield for the trailing twelve months is around 4.50%.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
BMY Bristol-Myers Squibb Company | 4.50% | 4.60% | 4.24% | 4.44% | 3.00% | 2.36% | 3.69% | 2.55% | 3.08% | 2.55% | 1.95% | 2.17% |
MIRA MIRA Pharmaceuticals Inc. Common Stock | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Financials
MIRA vs. BMY - Financials Comparison
This section allows you to compare key financial metrics between MIRA Pharmaceuticals Inc. Common Stock and Bristol-Myers Squibb Company. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
Frequently Asked Questions
MIRA and BMY have a correlation of 0.12, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
MIRA has higher volatility (21.60%) compared to BMY (8.49%). In terms of maximum drawdown, MIRA dropped -92.69% vs BMY's -72.03%.
BMY currently has the higher Sharpe Ratio (0.90 vs -0.23), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for MIRA and BMY
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer